ORPHAN SHAREHOLDERS APPROVE MERGER

Orphan Medical shareholders voted Wednesday to approve the company's sale to Jazz Pharmaceuticals, the company announced. The company said shareholders representing 61.4 percent of its outstanding shares, voted by a margin of about 94 percent to 6 percent to approve the deal. Jazz Pharmaceuticals of Palo Alto, Calif., agreed to buy Orphan for approximately $122.6 million in deal first announced in April. Minnetonka-based Orphan makes Xyrem, a drug used to treat the sleep disorder narcolepsy.

Minneapolis/St. Paul Business Journal

(http://twincities.bizjournals.com/twincities/stories/2005/06/20/daily33.html)